Porter CJH - Search Results

1

Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers.

Haque S, McLeod VM, Jones S, Fung S, Whittaker M, McIntosh M, Pouton C, Owen DJ, Porter CJH, Kaminskas LM. Haque S, et al. Among authors: porter cjh. Eur J Pharm Biopharm. 2017 Oct;119:408-418. doi: 10.1016/j.ejpb.2017.07.005. Epub 2017 Jul 13. Eur J Pharm Biopharm. 2017. PMID: 28713018

2

Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid.

McIntosh MP, Porter CJ, Wasan KM, Ramaswamy M, Charman WN. McIntosh MP, et al. J Pharm Sci. 1999 Mar;88(3):378-84. doi: 10.1021/js980152g. J Pharm Sci. 1999. PMID: 10052998

3

Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model.

McIntosh MP, Batey AJ, Coker SJ, Porter CJ, Charman WN. McIntosh MP, et al. J Pharm Pharmacol. 2004 Jan;56(1):69-77. doi: 10.1211/0022357022520. J Pharm Pharmacol. 2004. PMID: 14980003

4

Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins.

McIntosh MP, Charman WN, Campbell M, Porter CJ. McIntosh MP, et al. J Control Release. 2004 Mar 5;95(2):275-89. doi: 10.1016/j.jconrel.2003.12.003. J Control Release. 2004. PMID: 14980776

5

Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.

Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJ. Boyd BJ, et al. Mol Pharm. 2006 Sep-Oct;3(5):614-27. doi: 10.1021/mp060032e. Mol Pharm. 2006. PMID: 17009860

6

Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.

Cuiné JF, Charman WN, Pouton CW, Edwards GA, Porter CJ. Cuiné JF, et al. Pharm Res. 2007 Apr;24(4):748-57. doi: 10.1007/s11095-006-9194-z. Epub 2007 Feb 15. Pharm Res. 2007. PMID: 17372700

7

Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.

Kaminskas LM, Boyd BJ, Karellas P, Henderson SA, Giannis MP, Krippner GY, Porter CJ. Kaminskas LM, et al. Mol Pharm. 2007 Nov-Dec;4(6):949-61. doi: 10.1021/mp070047s. Epub 2007 Oct 23. Mol Pharm. 2007. PMID: 17953445

8

Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.

Cuiné JF, McEvoy CL, Charman WN, Pouton CW, Edwards GA, Benameur H, Porter CJ. Cuiné JF, et al. J Pharm Sci. 2008 Feb;97(2):995-1012. doi: 10.1002/jps.21246. J Pharm Sci. 2008. PMID: 18064698

9

Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.

Pouton CW, Porter CJ. Pouton CW, et al. Adv Drug Deliv Rev. 2008 Mar 17;60(6):625-37. doi: 10.1016/j.addr.2007.10.010. Epub 2007 Nov 4. Adv Drug Deliv Rev. 2008. PMID: 18068260 Review.

10

Enhancing intestinal drug solubilisation using lipid-based delivery systems.

Porter CJ, Pouton CW, Cuine JF, Charman WN. Porter CJ, et al. Adv Drug Deliv Rev. 2008 Mar 17;60(6):673-91. doi: 10.1016/j.addr.2007.10.014. Epub 2007 Nov 7. Adv Drug Deliv Rev. 2008. PMID: 18155801 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

249 results

Search Page

Filters